Clinical Trials Logo

Filter by:
  • Terminated  
  • Page [1] ·  Next »
NCT ID: NCT05602727 Terminated - Alzheimer's Disease Clinical Trials

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Start date: December 2, 2022
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess is to evaluate the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.

NCT ID: NCT05466240 Terminated - Dengue Fever Clinical Trials

Study of AT-752 in Patients With Dengue Infection

Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

NCT ID: NCT05252910 Terminated - COVID-19 Clinical Trials

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents

CoVacSpec
Start date: January 1, 2022
Phase:
Study type: Observational

This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive locally authorized or licensed COVID-19 vaccines. Approximately 1,000 participants will be enrolled. Plasma and peripheral blood mononuclear cell samples will be obtained either by venipuncture, or by leukapheresis. Serum, RNA, and DNA samples will be obtained by venipuncture. Specimens for mucosal antibody assessments will be collected by nasal swabbing. Biological specimens will be collected from study participants at Baseline prior to the COVID-19 vaccine dose and at timepoints aligned with the study participant's vaccination schedule for a period of up to 1 year following receipt of the initial COVID-19 vaccination.

NCT ID: NCT05232864 Terminated - Lupus Nephritis Clinical Trials

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Start date: August 22, 2022
Phase: Phase 3
Study type: Interventional

The purpose is to provide treatment with secukinumab delivered subcutaneously (s.c.) via pre-filled syringe (PFS) for participants who complete study treatment until the Week 104 of the core study CAIN457Q12301 and to obtain long term efficacy, safety and tolerability data

NCT ID: NCT05014919 Terminated - Depression Clinical Trials

Vortioxetine to Prevent Return of Symptoms in Children With Depression

Start date: August 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.

NCT ID: NCT05011513 Terminated - COVID-19 Clinical Trials

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Start date: August 25, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.

NCT ID: NCT04927247 Terminated - Sickle Cell Disease Clinical Trials

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.

NCT ID: NCT04784559 Terminated - COVID-19 Infection Clinical Trials

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Neptuno
Start date: June 4, 2021
Phase: Phase 3
Study type: Interventional

Treatment of patients hospitalised for management of moderate COVID-19 infection

NCT ID: NCT04734873 Terminated - Covid-19 Clinical Trials

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Start date: February 25, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.

NCT ID: NCT04680637 Terminated - Clinical trials for Active Systemic Lupus Erythematosus

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.